AU2021289163B2 - 4-oxo-3,4-dihydroquinazolinon compounds for the treatment of BRAF-associated diseases and disorders - Google Patents

4-oxo-3,4-dihydroquinazolinon compounds for the treatment of BRAF-associated diseases and disorders Download PDF

Info

Publication number
AU2021289163B2
AU2021289163B2 AU2021289163A AU2021289163A AU2021289163B2 AU 2021289163 B2 AU2021289163 B2 AU 2021289163B2 AU 2021289163 A AU2021289163 A AU 2021289163A AU 2021289163 A AU2021289163 A AU 2021289163A AU 2021289163 B2 AU2021289163 B2 AU 2021289163B2
Authority
AU
Australia
Prior art keywords
formula
braf
cancer
compound
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2021289163A
Other languages
English (en)
Other versions
AU2021289163A1 (en
Inventor
Tanna Marie BETTENDORF
Patrick Michael DOERNER BARBOUR
Dean Russell KAHN
Alex Andrew KELLUM
Ellen Ruth Laird
David Austin MORENO
Li Ren
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Array Biopharma Inc
Original Assignee
Array Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Array Biopharma Inc filed Critical Array Biopharma Inc
Publication of AU2021289163A1 publication Critical patent/AU2021289163A1/en
Application granted granted Critical
Publication of AU2021289163B2 publication Critical patent/AU2021289163B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/90—Oxygen atoms with acyclic radicals attached in position 2 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
AU2021289163A 2020-06-09 2021-06-04 4-oxo-3,4-dihydroquinazolinon compounds for the treatment of BRAF-associated diseases and disorders Active AU2021289163B2 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063036522P 2020-06-09 2020-06-09
US63/036,522 2020-06-09
US202063116204P 2020-11-20 2020-11-20
US63/116,204 2020-11-20
US202163175655P 2021-04-16 2021-04-16
US63/175,655 2021-04-16
PCT/IB2021/054919 WO2021250521A1 (en) 2020-06-09 2021-06-04 4-oxo-3,4-dihydroquinazolinon compounds for the treatment of braf-associated diseases and disorders

Publications (2)

Publication Number Publication Date
AU2021289163A1 AU2021289163A1 (en) 2022-12-22
AU2021289163B2 true AU2021289163B2 (en) 2024-05-02

Family

ID=76355554

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021289163A Active AU2021289163B2 (en) 2020-06-09 2021-06-04 4-oxo-3,4-dihydroquinazolinon compounds for the treatment of BRAF-associated diseases and disorders

Country Status (20)

Country Link
US (2) US12303509B2 (https=)
EP (1) EP4161907A1 (https=)
JP (2) JP7312335B2 (https=)
KR (1) KR102904179B1 (https=)
CN (1) CN116096710B (https=)
AU (1) AU2021289163B2 (https=)
CL (1) CL2022003326A1 (https=)
CO (1) CO2022017876A2 (https=)
CR (1) CR20220626A (https=)
DO (1) DOP2022000282A (https=)
EC (1) ECSP22093029A (https=)
IL (1) IL298300B1 (https=)
MX (1) MX2022015703A (https=)
PE (1) PE20231651A1 (https=)
PY (1) PY2146661A (https=)
TW (2) TWI837478B (https=)
UA (1) UA130198C2 (https=)
UY (1) UY39261A (https=)
WO (1) WO2021250521A1 (https=)
ZA (1) ZA202212876B (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7667097B2 (ja) 2019-06-14 2025-04-22 ヤンセン ファーマシューティカ エヌ．ベー． 置換ピラゾロ－ピリジンアミド及びｇｌｕｎ２ｂ受容体調節因子としてのその使用
KR20220024403A (ko) 2019-06-14 2022-03-03 얀센 파마슈티카 엔.브이. 치환된 피라졸로-피라진 및 이들의 glun2b 수용체 조절제로서의 용도
PL4073065T3 (pl) 2019-12-10 2025-05-19 F. Hoffmann-La Roche Ag Nowe pochodne metylochinazolinonu
PH12022551118A1 (en) * 2019-12-10 2023-09-18 Hoffmann La Roche New braf inhibitors as paradox breakers
WO2021250521A1 (en) * 2020-06-09 2021-12-16 Array Biopharma Inc. 4-oxo-3,4-dihydroquinazolinon compounds for the treatment of braf-associated diseases and disorders
JP7834721B2 (ja) 2020-08-28 2026-03-24 アルビナス・オペレーションズ・インコーポレイテッド 急速進行性線維肉腫タンパク質分解化合物及び関連する使用方法
WO2022129259A1 (en) 2020-12-18 2022-06-23 F. Hoffmann-La Roche Ag New quinazolinone derivatives
TWI825637B (zh) 2021-03-31 2023-12-11 美商輝瑞股份有限公司 啶－１，６（２ｈ，７ｈ）－二酮
WO2022261250A1 (en) 2021-06-08 2022-12-15 C4 Therapeutics, Inc. Therapeutics for the degradation of mutant braf
EP4444710A1 (en) * 2021-12-08 2024-10-16 Array BioPharma Inc. Crystalline form of n-(2-chloro-3-((5-chloro-3-methyl-4-oxo-3,4-dihydroquinazolin-6-yl)amino)-4-fluorophenyl)-3-fluoroazetidine-1-sulfonamide
CA3255688A1 (en) * 2022-03-17 2023-09-21 St. Jude Children's Research Hospital TREATMENT OF A LOW-QUALITY GILOMA WITH MIRDAMETIN B
WO2023183470A1 (en) * 2022-03-24 2023-09-28 Vibliome Therapeutics, Llc Modulators of protein kinases
WO2023230554A1 (en) 2022-05-25 2023-11-30 Pfizer Inc. Combination of a braf inhibitor, an egfr inhibitor, and a pd-1 antagonist for the treatment of braf v600e-mutant, msi-h/dmmr colorectal cancer
CN117304205A (zh) * 2022-06-20 2023-12-29 中国科学院广州生物医药与健康研究院 一种苯并咪唑类三元并环化合物、其药学上可接受的盐及其应用
EP4584258A1 (en) 2022-09-07 2025-07-16 Arvinas Operations, Inc. Rapidly accelerated fibrosarcoma (raf) degrading compounds and associated methods of use
CN120359214A (zh) * 2022-12-15 2025-07-22 豪夫迈·罗氏有限公司 用于癌症治疗的组合疗法
WO2024218632A1 (en) 2023-04-17 2024-10-24 Array Biopharma Inc. Erk protein kinase inhibitors
WO2025014933A1 (en) * 2023-07-10 2025-01-16 Northwestern University Targeting tim-3 in mapk-driven glioma
WO2025108405A1 (zh) * 2023-11-22 2025-05-30 西藏海思科制药有限公司 作为激酶抑制剂的喹唑啉酮衍生物的制备及其用途
WO2025176139A1 (zh) * 2024-02-20 2025-08-28 海思科医药集团股份有限公司 一种喹唑啉酮衍生物的晶型及其制备方法和应用
WO2026037755A1 (en) * 2024-08-13 2026-02-19 F. Hoffmann-La Roche Ag New methylquinazolinone derivatives

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012118492A1 (en) * 2011-03-01 2012-09-07 Array Biopharma Inc. Heterocyclic sulfonamides as raf inhibitors
WO2020261156A1 (en) * 2019-06-28 2020-12-30 Array Biopharma Inc. Quinazolin-4-one derivatives useful for the treatment of braf-associated diseases and disorders

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG2013013339A (en) 2002-03-13 2014-12-30 Array Biopharma Inc N3 alkylated benzimidazole derivatives as mek inhibitors
US7144907B2 (en) 2003-09-03 2006-12-05 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
US7517994B2 (en) 2003-11-19 2009-04-14 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
CA2546353A1 (en) 2003-11-19 2005-06-09 Array Biopharma Inc. Bicyclic inhibitors of mek and methods of use thereof
US7732616B2 (en) 2003-11-19 2010-06-08 Array Biopharma Inc. Dihydropyridine and dihydropyridazine derivatives as inhibitors of MEK and methods of use thereof
BRPI0514691A (pt) 2004-08-31 2008-06-17 Astrazeneca Ab composto ou um sal farmaceuticamente aceitável do mesmo, processo para preparar o mesmo, composição farmacêutica, e, uso de um composto ou um sal farmaceuticamente aceitável do mesmo
SG177981A1 (en) 2005-05-18 2012-02-28 Array Biopharma Inc 4-(phenylamino)-6-oxo-1, 6-dihydropyridazine-3-carboxamide derivatives as mek inhibitors for the treatment of hyperproliferative diseases
WO2007113557A1 (en) 2006-04-05 2007-10-11 Astrazeneca Ab Substituted quinazolines with anti-cancer activity
CN101415688A (zh) 2006-04-05 2009-04-22 阿斯利康(瑞典)有限公司 具有b-raf抑制活性的喹唑啉酮衍生物
CN101421253A (zh) 2006-04-18 2009-04-29 阿斯利康(瑞典)有限公司 喹唑啉-4-酮衍生物、其制备方法及含有它们的药用组合物
PE20081581A1 (es) 2006-12-21 2008-11-12 Plexxikon Inc COMPUESTOS PIRROLO[2,3-b]PIRIDINAS COMO MODULADORES DE QUINASA
JP2010533729A (ja) 2007-07-17 2010-10-28 プレキシコン，インコーポレーテッド キナーゼ調節のための化合物と方法、及びそのための適応
SI2324008T1 (sl) 2008-07-24 2012-08-31 Nerviano Medical Sciences Srl 3,4-diarilpirazoli kot protein-kinazni inhibitorji
JO3002B1 (ar) 2009-08-28 2016-09-05 Irm Llc مركبات و تركيبات كمثبطات كيناز بروتين
CN108542906A (zh) 2011-11-11 2018-09-18 诺华股份有限公司 治疗增生性疾病的方法
CA3008312A1 (en) 2016-01-06 2017-07-13 Trillium Therapeutics Inc. Novel fluorinated quinazoline derivatives as egfr inhibitors
JP7219218B2 (ja) 2016-12-22 2023-02-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規のベンジルアミノ置換キナゾリンおよびｓｏｓ１阻害剤としての誘導体
EP3684772B1 (en) 2017-09-20 2023-12-06 ABM Therapeutics Corporation Cyclic iminopyrimidine derivatives as kinase inhibitors
WO2019071351A1 (en) 2017-10-12 2019-04-18 Trillium Therapeutics Inc. NOVEL 4-ARYLOXYQUINAZOLINE FLUORIN DERIVATIVES AS EGFR INHIBITORS USEFUL FOR THE TREATMENT OF CANCERS
RU2678455C1 (ru) 2018-06-01 2019-01-29 Сергей Викторович Леонов Кристаллическая форма n-(3-(5-(4-хлорофенил)-1н-пиразоло[3,4-в]пиридин-3-карбонил)-2,4-дифторофенил) пропан-1-сульфонамида, активный компонент, фармацевтическая композиция и лекарственное средство
WO2020055992A1 (en) 2018-09-11 2020-03-19 NetraDyne, Inc. Inward/outward vehicle monitoring for remote reporting and in-cab warning enhancements
PH12022551118A1 (en) * 2019-12-10 2023-09-18 Hoffmann La Roche New braf inhibitors as paradox breakers
PL4073065T3 (pl) 2019-12-10 2025-05-19 F. Hoffmann-La Roche Ag Nowe pochodne metylochinazolinonu
WO2021250521A1 (en) * 2020-06-09 2021-12-16 Array Biopharma Inc. 4-oxo-3,4-dihydroquinazolinon compounds for the treatment of braf-associated diseases and disorders

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012118492A1 (en) * 2011-03-01 2012-09-07 Array Biopharma Inc. Heterocyclic sulfonamides as raf inhibitors
WO2020261156A1 (en) * 2019-06-28 2020-12-30 Array Biopharma Inc. Quinazolin-4-one derivatives useful for the treatment of braf-associated diseases and disorders

Also Published As

Publication number Publication date
CL2022003326A1 (es) 2023-02-24
TW202214577A (zh) 2022-04-16
DOP2022000282A (es) 2023-03-31
IL298300B1 (en) 2026-02-01
US20220288074A1 (en) 2022-09-15
JP2023123854A (ja) 2023-09-05
PE20231651A1 (es) 2023-10-17
JP7312335B2 (ja) 2023-07-20
JP2023524910A (ja) 2023-06-13
TWI837478B (zh) 2024-04-01
NZ795045A (en) 2025-05-30
ECSP22093029A (es) 2023-02-28
PY2146661A (es) 2022-10-20
US12303509B2 (en) 2025-05-20
CN116096710A (zh) 2023-05-09
IL298300A (en) 2023-01-01
EP4161907A1 (en) 2023-04-12
MX2022015703A (es) 2023-01-24
CA3186343A1 (en) 2021-12-16
WO2021250521A1 (en) 2021-12-16
US20250241915A1 (en) 2025-07-31
ZA202212876B (en) 2024-10-30
CR20220626A (es) 2023-01-23
UY39261A (es) 2022-01-31
TW202426436A (zh) 2024-07-01
CN116096710B (zh) 2025-07-25
CO2022017876A2 (es) 2022-12-20
KR102904179B1 (ko) 2025-12-26
KR20230019944A (ko) 2023-02-09
BR112022024597A2 (pt) 2022-12-27
UA130198C2 (uk) 2025-12-17
AU2021289163A1 (en) 2022-12-22

Similar Documents

Publication Publication Date Title
AU2021289163B2 (en) 4-oxo-3,4-dihydroquinazolinon compounds for the treatment of BRAF-associated diseases and disorders
US11634409B2 (en) Compounds for the treatment of BRAF-associated diseases and disorders
AU2022250102B2 (en) 3,4-dihydro-2,7-naphthyridine-1,6(2h,7h)-diones as mek inhibitors
CA3186343C (en) 4-oxo-3,4-dihydroquinazolinon compounds for the treatment of braf-associated diseases and disorders
RU2814662C1 (ru) Соединения 4-оксо-3,4-дигидрохиназолинона для лечения braf-ассоциированных заболеваний и нарушений
OA21023A (en) 4-oxo-3,4-dihydroquinazolinon compounds for the treatment of BRAF-associated diseases and disorders.
BR112022024597B1 (pt) Compostos de 4-oxo-3,4-di-hidroquinazolinona para o tratamento de doenças e distúrbios associados com braf, composições e usos dos mesmos
EA046758B1 (ru) Соединения 4-оксо-3,4-дигидрохиназолинона для лечения braf-ассоциированных заболеваний и расстройств
RU2797606C1 (ru) Производные хиназолин-4-она, полезные для лечения braf-ассоциированных заболеваний и нарушений
EA047982B1 (ru) 3,4-дигидро-2,7-нафтиридин-1,6(2h,7h)-дионы в качестве ингибиторов mek

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)